Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ertafolide
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Ertafolide is an investigational imaging agent designed to target the folate receptor (FR), which is overexpressed in many cancers such as ovarian and endometrial cancer. It is used primarily as a diagnostic tool to identify patients whose tumors express the folate receptor and who may benefit from targeted therapies like vintafolide. Ertafolide binds specifically to the folate receptor on cancer cells and can be visualized using imaging techniques, aiding in patient selection for FR-targeted treatments[2][5].
- Brand names
- FolateScan
- Other names
- EC20EC-20EC 20FolateScanertafolide
02
Targets
FOLR3 (Folate receptor gamma)FOLR2 (Folate receptor beta)FOLR1 (FRα)
Beyond the preview
Go deeper on Ertafolide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ertafolide.